Peringatan Keamanan

Clinical trial results suggested a favorable overall safety profile for interferon omega.

Human interferon omega-1

DB05472

biotech investigational

Deskripsi

Human interferon omega 1 (IFN-omega 1 = IFN-alpha II1) is a recently discovered protein structurally related to IFN-alpha and -beta. It occurs naturally in the human body and is currently being manufactured by Intarcia through genetic engineering. There are multiple routes for administration of omega interferon: injection, an implantable subcutaneous drug delivery system, and an oral formulation. It has been investigated both in single and combination treatment. The biological activities of IFN-omega 1 and its physiological role are not known to date.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

489 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Human interferon omega-1.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Human interferon omega-1.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Human interferon omega-1.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Human interferon omega-1.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Human interferon omega-1.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Human interferon omega-1.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Human interferon omega-1.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Human interferon omega-1.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Human interferon omega-1.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Human interferon omega-1.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Human interferon omega-1.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human interferon omega-1.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Human interferon omega-1.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Human interferon omega-1.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Human interferon omega-1.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Human interferon omega-1.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Human interferon omega-1.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Human interferon omega-1.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Human interferon omega-1.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Human interferon omega-1.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Human interferon omega-1.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Human interferon omega-1.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Human interferon omega-1.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Human interferon omega-1.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Human interferon omega-1.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Human interferon omega-1.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Human interferon omega-1.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Human interferon omega-1.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Human interferon omega-1.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Human interferon omega-1.
Cladribine Human interferon omega-1 may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Human interferon omega-1.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Human interferon omega-1.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Human interferon omega-1.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Human interferon omega-1.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Human interferon omega-1.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Human interferon omega-1.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Human interferon omega-1.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Human interferon omega-1.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Human interferon omega-1.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Human interferon omega-1.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Human interferon omega-1.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Human interferon omega-1.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Human interferon omega-1.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Human interferon omega-1.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Human interferon omega-1.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Human interferon omega-1.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Human interferon omega-1.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Human interferon omega-1.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Human interferon omega-1.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Human interferon omega-1.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Human interferon omega-1.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Human interferon omega-1.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Human interferon omega-1.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Human interferon omega-1.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Human interferon omega-1.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Human interferon omega-1.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Human interferon omega-1.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Human interferon omega-1.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Human interferon omega-1.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Human interferon omega-1.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Human interferon omega-1.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Human interferon omega-1.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Human interferon omega-1.
Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Human interferon omega-1.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Human interferon omega-1.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Human interferon omega-1.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Human interferon omega-1.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Human interferon omega-1.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Human interferon omega-1.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Human interferon omega-1.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Human interferon omega-1.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Human interferon omega-1.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Human interferon omega-1.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Human interferon omega-1.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Human interferon omega-1.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Human interferon omega-1.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Human interferon omega-1.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Human interferon omega-1.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Human interferon omega-1.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Human interferon omega-1.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Human interferon omega-1.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Human interferon omega-1.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Human interferon omega-1.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Human interferon omega-1.
Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Human interferon omega-1.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Human interferon omega-1.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Human interferon omega-1.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Human interferon omega-1.
Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Human interferon omega-1.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Human interferon omega-1.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Human interferon omega-1.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Human interferon omega-1.
Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Human interferon omega-1.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Human interferon omega-1.
Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Human interferon omega-1.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Human interferon omega-1.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Human interferon omega-1.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Human interferon omega-1.
Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Human interferon omega-1.

Target Protein

Interferon alpha/beta receptor 1 IFNAR1
Interferon alpha/beta receptor 2 IFNAR2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 16987555
    Buckwold VE, Wei J, Huang Z, Huang C, Nalca A, Wells J, Russell J, Collins B, Ptak R, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P: Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Res. 2007 Feb;73(2):118-25. Epub 2006 Sep 11.
  • PMID: 15652968
    Okuse C, Rinaudo JA, Farrar K, Wells F, Korba BE: Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. Antiviral Res. 2005 Jan;65(1):23-34.
  • PMID: 15621727
    Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC: Human interferons alpha, beta and omega. Growth Factors. 2004 Dec;22(4):243-51. doi: 10.1080/08977190400000833.
  • PMID: 1647209
    Adolf GR, Fruhbeis B, Hauptmann R, Kalsner I, Maurer-Fogy I, Ostermann E, Patzelt E, Schwendenwein R, Sommergruber W, Zophel A: Human interferon omega 1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein. Biochim Biophys Acta. 1991 Jun 13;1089(2):167-74. doi: 10.1016/0167-4781(91)90004-6.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul